Published
Scott B. Sellinger, MD, FACS, President of Advanced Urology Institute in Tallahassee, Florida, addresses key considerations in deciding between doublet and triplet therapies for metastatic castration-sensitive prostate cancer. In this 12-minute presentation, Dr. Sellinger highlights the superiority of androgen deprivation therapy (ADT) combined with androgen pathway inhibitors, offering superior survival benefits compared to ADT alone.
- Categoria
- Urology
Commenta per primo questo video.
Prossimo
-
08:21
Scott Adams PLEADS With Trump To Schedule CANCER TREATMENT | RISING+
-
09:15
Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC
-
15:54
The psychology of self-motivation | Scott Geller | TEDxVirginiaTech
-
11:34
New TIL Therapy Trial Options: PD1 Knockout TIL Therapy
-
05:48
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
-
17:45
Demystifying psychodynamic therapy
-
18:29
A PCa Case of PSA Rising After RP, Salvage XRT, ADT & a Case of Rising PSA After Triplet Therapy
-
05:32
Why MRI matters in radiation therapy
-
08:09
Optimizing Sequential Therapy in Advanced RCC
-
05:13
Applications of SiRNA for cancer therapy
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
